Eighteen nucleic acid therapeutics have been approved for treatment of various diseases in
the last 25 years. Their modes of action include antisense oligonucleotides (ASOs), splice …

mRNA vaccines have been demonstrated as a powerful alternative to traditional
conventional vaccines because of their high potency, safety and efficacy, capacity for rapid …

Modern drug delivery technology began in 1952 with the advent of the Spansule® sustained-
release capsule technology, which can deliver a drug for 12 h after oral administration …

Harnessing mRNA–lipid nanoparticles (LNPs) to treat patients with cancer has been an
ongoing research area that started before these versatile nanoparticles were successfully …

Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …

Abstract mRNA vaccines have evolved from being a mere curiosity to emerging as COVID-
19 vaccine front-runners. Recent advancements in the field of RNA technology, vaccinology …

The host immune system is highly compromised in case of viral infections and relapses are
very common. The capacity of the virus to destroy the host cell by liberating its own DNA or …

Nucleic Acid (NA) based therapeutics are poised to disrupt modern medicine and augment
traditional pharmaceutics in a meaningful way. However, a key challenge to advancing NA …

Intracellular delivery is a key step in biological research and has enabled decades of
biomedical discoveries. It is also becoming increasingly important in industrial and medical …

The first published description of therapeutic applications of antisense oligonucleotide
(ASO) technology occurred in the late 1970s and was followed by the founding of …